| Health / Medical Topics |
p38 MAPK Inhibitor LY3007113
An orally active p38 mitogen-activated protein kinase (MAPK) inhibitor with potential immunomodulating, anti-inflammatory, and antineoplastic activity. Upon administration, LY3007113 inhibits the activity of p38, thereby preventing p38 MAPK-mediated signaling. This may result in the inhibition of the production of proinflammatory cytokines and the induction of tumor cell apoptosis. p38 MAPK, a serine/threonine protein kinase often upregulated in cancer cells, plays a crucial part in the production of a variety of cytokines involved in inflammation and cellular proliferation such as tumor necrosis factor (TNF) and interleukin (IL)-1 and -6. (NCI Thesaurus)
YOU MAY ALSO LIKE
The dimesylate salt form of LY2228820, a tri-substituted imidazole derivative and orally available, p38 mitogen-activated protein kinase (MAPK) inhibitor with potential anti-inflammatory…
Funds awarded to certain U.S. institutions by the National Cancer Institute (NCI) for them to become cancer centers in the United States,…
P2Y purinoceptor 8 (359 aa, ~41 kDa) is encoded by the human P2RY8 gene. This protein plays a role in signal…
P2Y purinoceptor 2 (377 aa, ~42 kDa) is encoded by the human P2RY2 gene. This protein plays a role in ligand-dependent activation…
A fusion gene that results from an intrachromosomal deletion of the pseudoautosomal region 1of Xp22.3 and Yp11.3 which fuses the noncoding exon…
Human P2RY8 wild-type allele is located in the vicinity of Xp22.33 and Yp11.3 and is approximately 75 kb in length. This allele,…
